Understanding Concomitant Components in Pharmaceutical Excipients: Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.
| Publicado en: | Pharmaceutical Technology Vol. 45; no. 2; pp. 49 - 54 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MJH Life Sciences
Feb2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=148509016&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 148509016 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15432521 4FK jtl: Pharmaceutical Technology issn: 15432521 maglogo: N pubinfo: dt: Feb2021 vid: 45 iid: 2 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 148509016 148509016 ppf: 49 ppct: 5 formats: fmt: @attributes: type: P tig: atl: Understanding Concomitant Components in Pharmaceutical Excipients: Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition. aug: au: Putnam, Jennifer Ullman, Katherine Zawislak, Priscilla Schoneker, David Collins, George Muse, Douglas G. Carlin, Brian Zeleznik, Joseph Moreton, Chris affil: AR&D supervisor II, Perrigo sug: pubtype: Trade Publication doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|